Gelonghui, January 26 | Shuanglu Pharmaceutical (002038.SZ) announced its 2023 annual results forecast. Net profit and profit attributable to shareholders of listed companies during the reporting period was about 39 million yuan to 47 million yuan, an increase of about 66%-100% over the same period of the previous year; net profit after deducting non-recurring profit and loss was about 20 million yuan to 250 million yuan, an increase of about 40%-75% over the same period last year; basic earnings per share were about 0.38 yuan/share - 0.46 yuan/share.
During the reporting period, the company's net profit attributable to shareholders of listed companies increased significantly. First, changes in fair value arising from the company's non-recurring profit and loss, held transactional financial assets and financial assets that can be sold have a large impact, which ranges between 170 million yuan and 20 million yuan; second, changes in the company's product structure. The number of newly listed products is large and contributes greatly to revenue and profits, and the net profit growth brought about by the main business affects the amount of about 60 million yuan to 10 million yuan.